Alkermes plc
ALKSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeAlkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in. Valued at $7.32B, ALKS is a mid-cap name in its sector. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Market Cap
$7.32B
Beta
0.27
P/E (TTM)
114.82
P/E (Fwd)
24.13
EPS (TTM)
$0.38
EPS (Fwd)
$1.81
ROE
3.9%
ROA
4.2%
Cash
$656.6M
Total Debt
$1.57B
Free CF
$153.4M
52W Change
46.8%
Annual Financials
Cash vs Debt
Where ALKS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ALKS finished 0.92% above its 150-day moving average ($42.58) and 7.99% above its 200-day moving average ($39.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALKS overbought or oversold?
At the October 20, 2026 close, ALKS's RSI(14) was 59.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Alkermes plc carries $1.57B in total debt against $656.6M in cash reserves — debt is roughly 2.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $153.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 3.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $1.11B to $1.48B.
With a beta below 0.7, Alkermes plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. At over 50x earnings, ALKS carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Alkermes plc's trajectory.